Logo

International Genomics Consortium Names Michael Berens as CEO

Mar 21, 2003

NEW YORK, March 21 -- Michael Berens, a researcher at Arizona's Translational Genomics Research Institute, has become CEO of the International Genomics Consortium, the IGC said today.

 

His first task will be to talk to potential partners, such as pharmaceutical companies, and to raise funds for the consortium, according to an IGC spokesperson.

 

Berens, a former researcher at the Barrow Neurological Institute, will keep his position as senior investigator at the Translational Genomics Research Institute in order to be able to pursue federally funded research.

 

Further, the Phoenix, Ariz.-based consortium named Robert Penny as chief medical officer, Michael Bittner as chief research officer, and Michael Rodgers as chief financial officer. In addition, Max Poll, president and CEO at Scottsdale Healthcare, was elected to the IGC's board.

 

The IGC, a non-profit medical research foundation, is planning to collect tissue samples from a variety of sources and analyze them using genomics technologies. Its first project will be to study gene expression in cancer.

Breaking News
The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.